SCHEMBL22845314

SCHEMBL22845314

CNC(=O)c1ccc(-n2c(=O)c3c(n4ncc(Cc5ccc(OC(F)(F)F)cc5)c24)CNCC3)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCGR P47871 6/20 0.41
MAPT P10636 3/20 0.37
POLB P06746 1/20 0.37
GIPR P48546 2/20 0.37
SLC6A2 P23975 1/20 0.35
SLC6A4 P31645 1/20 0.35
KCNH2 Q12809 2/20 0.35
NTRK1 P04629 1/20 0.35
NTRK3 Q16288 1/20 0.35
NTRK2 Q16620 1/20 0.35
HTR2C P28335 1/20 0.35
EPHX2 P34913 2/20 0.34
FAAH O00519 1/20 0.34
RAF1 P04049 1/20 0.34
TRPM8 Q7Z2W7 1/20 0.34
PLAT P00750 1/20 0.34
NR1H4 Q96RI1 1/20 0.34
EGLN1 Q9GZT9 1/20 0.34
SCN9A Q15858 2/20 0.34
P2RY1 P47900 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24469835 0.87 CRBN (0.39) HTR2C
SCHEMBL22717418 0.86 EGLN1 (0.37) KCNH2EGLN1SCN9A
Trifluoroacetic Acid SCHEMBL22717821 0.86 CTNNB1 (0.34) EGLN1
SCHEMBL22845221 0.83 GCGR (0.40) GCGRMAPTPOLBGIPRKCNH2
SCHEMBL24470064 0.83 HSP90AA1 (0.34)
SCHEMBL22845200 0.81 GCGR (0.38) GCGRMAPTPOLBGIPRSLC6A4
Trifluoroacetic Acid SCHEMBL29670253 0.81 HSP90AA1 (0.33)
SCHEMBL24469782 0.81 HSP90AA1 (0.35)
SCHEMBL24469920 0.81 HSP90AA1 (0.35)
SCHEMBL24483837 0.80 GCGR (0.38) GCGRMAPTPOLBGIPRHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220000874-A1 TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2022-01-06 US disclosed
US-11136321-B2 Tricyclic compounds ALIGOS THERAPEUTICS, INC. (US) 2021-10-05 US disclosed
US-20200407361-A1 TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2020-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220000874-A1 TRICYCLIC COMPOUNDS SLC10A1, PKD1, CEL GCGR 1314/4885MAPT 651/4885POLB 3198/4885
US-11136321-B2 Tricyclic compounds SLC10A1, PKD1, CEL GCGR 1314/4885MAPT 651/4885POLB 3198/4885
US-20200407361-A1 TRICYCLIC COMPOUNDS SLC10A1, PKD1, CEL GCGR 1314/4885MAPT 651/4885POLB 3198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.